Long-Term Outcomes and Clinical Predictors of Mortality Following Occurrence of Stent Thrombosis.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
05 04 2022
Historique:
pubmed: 5 4 2022
medline: 8 4 2022
entrez: 4 4 2022
Statut: ppublish

Résumé

Background Stent thrombosis (ST) remains a significant medical issue. In particular, longer-term mortality and clinical predictors after ST occurrence have yet to be elucidated. Methods and Results This was a multicenter, retrospective, observational study. A total of 187 definite ST cases from January 2008 to December 2017 were enrolled, and the long-term clinical outcomes were investigated. The primary outcome measure was the cumulative mortality after ST occurrence. In addition, independent predictors of mortality were assessed. Among the stent types causing ST, bare-metal stent, first-generation drug-eluting stent, second-generation drug-eluting stent, and third-generation drug-eluting stent comprised 31.0%, 19.3%, 36.9%, and 6.4% of cases, respectively. Median duration from stent implantation to ST was 680.5 (interquartile range, 33.8-2450.5) days. Cumulative mortality was 14.6%, 17.4%, 21.2%, 24.4%, and 33.8% at 1, 2, 3, 5 and 10 years, respectively. The cumulative mortality did not significantly differ by type of stent, and mortality of late ST was higher than that of early ST and very late ST; however, it did not reach statistical significance after the multivariate analysis. Independent predictors of mortality were hemodialysis (hazard ratio [HR], 7.80; 95% CI, 3.07-19.81;

Identifiants

pubmed: 35377181
doi: 10.1161/JAHA.121.023276
pmc: PMC9075466
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e023276

Investigateurs

Motoo Date (M)
Tatsuhisa Ozaki (T)
Kohtaro Takayasu (K)
Naoki Mori (N)
Tomoaki Kobayashi (T)
Yuma Hamanaka (Y)
Takahisa Yamada (T)
Naotaka Okamoto (N)
Masaki Tsuda (M)
Osamu Nakagawa (O)
Isamu Mizote (I)
Kensuke Yokoi (K)
Tatsuya Shiraki (T)
Taiki Sato (T)
Akihiro Sunaga (A)
Bolrathanak Oeun (B)
Tomoharu Dohi (T)
Shinichiro Suna (S)
Tomohito Ohtani (T)
Toshihiro Takeda (T)
Hiroya Mizuno (H)
Yasushi Matsumura (Y)

Commentaires et corrections

Type : CommentIn

Références

Circ J. 2014;78(1):101-9
pubmed: 24189504
Cardiovasc Revasc Med. 2019 Jul;20(7):559-562
pubmed: 30217627
J Am Coll Cardiol. 2004 Jun 2;43(11):1959-63
pubmed: 15172398
BMJ. 2012 May 23;344:e3257
pubmed: 22623632
Circulation. 2012 Oct 16;126(16):2020-35
pubmed: 22923432
Circulation. 2007 May 1;115(17):2344-51
pubmed: 17470709
N Engl J Med. 2002 Jun 6;346(23):1773-80
pubmed: 12050336
Circ Rep. 2020 Dec 15;3(1):18-25
pubmed: 33693286
Circ Cardiovasc Interv. 2019 Jun;12(6):e007822
pubmed: 31177822
J Am Coll Cardiol. 2006 Mar 7;47(5):951-61
pubmed: 16516077
Cardiovasc Interv Ther. 2020 Apr;35(2):105-116
pubmed: 32125622
Int J Cardiol. 2013 Jun 5;166(1):193-7
pubmed: 22088222
JACC Cardiovasc Interv. 2015 Dec 28;8(15):1966-1974
pubmed: 26738667
Eur Heart J. 2015 Dec 14;36(47):3320-31
pubmed: 26417060
Eur Heart J. 2011 Apr;32(7):829-37
pubmed: 21196442
Eur Heart J. 1998 Aug;19(8):1214-23
pubmed: 9740343
Circulation. 2010 Jul 6;122(1):52-61
pubmed: 20566955
Lancet. 2004 Oct 23-29;364(9444):1519-21
pubmed: 15500897
Cardiovasc Interv Ther. 2020 Jan;35(1):1-12
pubmed: 31571149
J Invasive Cardiol. 2009 Oct;21(10):E191-6
pubmed: 19805850
JACC Cardiovasc Interv. 2013 Dec;6(12):1267-74
pubmed: 24355117

Auteurs

Takayuki Ishihara (T)

Kansai Rosai Hospital Cardiovascular Center Amagasaki Japan.

Katsuki Okada (K)

Department of Cardiovascular Medicine Osaka University Graduate School of Medicine Suita Japan.

Hirota Kida (H)

Department of Cardiovascular Medicine Osaka University Graduate School of Medicine Suita Japan.

Takuya Tsujimura (T)

Kansai Rosai Hospital Cardiovascular Center Amagasaki Japan.

Osamu Iida (O)

Kansai Rosai Hospital Cardiovascular Center Amagasaki Japan.

Shota Okuno (S)

Kansai Rosai Hospital Cardiovascular Center Amagasaki Japan.

Yosuke Hata (Y)

Kansai Rosai Hospital Cardiovascular Center Amagasaki Japan.

Taku Toyoshima (T)

Kansai Rosai Hospital Cardiovascular Center Amagasaki Japan.

Naoko Higashino (N)

Kansai Rosai Hospital Cardiovascular Center Amagasaki Japan.

Atsushi Kikuchi (A)

Division of Cardiology Osaka General Medical Center Osaka Japan.

Tetsuya Watanabe (T)

Division of Cardiology Osaka General Medical Center Osaka Japan.

Takashi Morita (T)

Division of Cardiology Osaka General Medical Center Osaka Japan.

Akihiro Tanaka (A)

Division of Cardiology Osaka Rosai Hospital Osaka Japan.

Ryu Shutta (R)

Division of Cardiology Osaka Rosai Hospital Osaka Japan.

Masami Nishino (M)

Division of Cardiology Osaka Rosai Hospital Osaka Japan.

Shumpei Kosugi (S)

Cardiovascular Division National Hospital Organization Osaka National Hospital Osaka Japan.

Yasunori Ueda (Y)

Cardiovascular Division National Hospital Organization Osaka National Hospital Osaka Japan.

Yasuhiro Ichibori (Y)

Cardiovascular Division Osaka Police Hospital Osaka Japan.

Yoshiharu Higuchi (Y)

Cardiovascular Division Osaka Police Hospital Osaka Japan.

Yohei Sotomi (Y)

Department of Cardiovascular Medicine Osaka University Graduate School of Medicine Suita Japan.

Daisuke Nakamura (D)

Department of Cardiovascular Medicine Osaka University Graduate School of Medicine Suita Japan.

Masahiro Kumada (M)

Department of Cardiology Toyonaka Municipal Hospital Toyonaka Japan.

Shungo Hikoso (S)

Department of Cardiovascular Medicine Osaka University Graduate School of Medicine Suita Japan.

Daisaku Nakatani (D)

Department of Cardiovascular Medicine Osaka University Graduate School of Medicine Suita Japan.

Toshiaki Mano (T)

Kansai Rosai Hospital Cardiovascular Center Amagasaki Japan.

Yasushi Sakata (Y)

Department of Cardiovascular Medicine Osaka University Graduate School of Medicine Suita Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH